GLYCOTOPE is a global leader in optimizing the glycosylation of biopharmaceuticals
GlycoExpress is one of the broadest platform technologies for the development and production of glycosylated proteins.
A clinical pipeline of 4 glycooptimized BioBetters and NBEs underlines GLYCOTOPE´s and its manufacturing arm GLYCOTOPE BIOTECHNOLOGY´s competence to contribute significant improvements to healthcare.
7.-9. October, 2014, Paris (France)
3.-4.- June, 2014, Lyon (France)
June 23-26, 2014, San Diego, CA
Glycotope Doses First Patients in Phase IIb Study with PankoMab-GEX™ for the Maintenance Therapy of Ovarian Carcinoma First therapeutic glycooptimized antibody against a novel tumor-specific carbohydrate-protein mixed epitope on a series of cancer cells Excellent tolerability, no significant toxicity and …
Berlin, Germany, November 18th, 2013 – Glycotope GmbH, a global leader in developing therapeutic antibodies targeting glycosylated epitopes on cancer cells and optimizing the sugar chains (glycosylation) of biopharmaceuticals, today announced results from the Phase II clinical trial with FSH-GEX™ …